- Home
- SILC vs ACHV Comparison
SILC vs ACHV Comparison
Compare SILC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- ACHV
- Stock Information
- Founded
- SILC 1987
- ACHV N/A
- Country
- SILC Israel
- ACHV Canada
- Employees
- SILC N/A
- ACHV N/A
- Industry
- SILC Computer Manufacturing
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SILC Technology
- ACHV Health Care
- Exchange
- SILC Nasdaq
- ACHV Nasdaq
- Market Cap
- SILC 91.4M
- ACHV 92.6M
- IPO Year
- SILC 1994
- ACHV N/A
- Fundamental
- Price
- SILC $13.97
- ACHV $2.42
- Analyst Decision
- SILC Hold
- ACHV Strong Buy
- Analyst Count
- SILC 2
- ACHV 4
- Target Price
- SILC N/A
- ACHV $15.75
- AVG Volume (30 Days)
- SILC 26.7K
- ACHV 159.3K
- Earning Date
- SILC 04-28-2025
- ACHV 05-08-2025
- Dividend Yield
- SILC N/A
- ACHV N/A
- EPS Growth
- SILC N/A
- ACHV N/A
- EPS
- SILC N/A
- ACHV N/A
- Revenue
- SILC $58,114,000.00
- ACHV N/A
- Revenue This Year
- SILC $6.22
- ACHV N/A
- Revenue Next Year
- SILC $19.10
- ACHV N/A
- P/E Ratio
- SILC N/A
- ACHV N/A
- Revenue Growth
- SILC N/A
- ACHV N/A
- 52 Week Low
- SILC $11.35
- ACHV $2.35
- 52 Week High
- SILC $18.24
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- SILC 33.70
- ACHV 34.37
- Support Level
- SILC $14.21
- ACHV $2.70
- Resistance Level
- SILC $15.37
- ACHV $2.99
- Average True Range (ATR)
- SILC 0.63
- ACHV 0.19
- MACD
- SILC -0.02
- ACHV -0.03
- Stochastic Oscillator
- SILC 4.44
- ACHV 10.49
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.